AlphaCrest Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

AlphaCrest Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,061	Closed	-$1.01M	–	56
2022 Q3	$1.01M	Sell	5,061 -483	-9%	-$92.1K	0.06%	603
2022 Q2	$809K	Buy	5,544 +1,781	+47%	+$253K	0.04%	756
2022 Q1	$614K	Buy	3,763 +974	+35%	+$148K	0.03%	793
2021 Q4	$473K	Sell	2,789 -2,119	-43%	-$394K	0.02%	1117
2021 Q3	$927K	Buy	4,908 +2,271	+86%	+$426K	0.05%	649
2021 Q2	$447K	Sell	2,637 -294	-10%	-$43.1K	0.02%	988
2021 Q1	$414K	Sell	2,931 -5,467	-65%	-$823K	0.02%	888
2020 Q4	$1.09M	Buy	+8,398	New	+$1.12M	0.09%	292
2020 Q3	–	Sell	-1,421	Closed	-$210K	–	1078
2020 Q2	$210K	Sell	1,421 -1,789	-56%	-$241K	0.03%	823
2020 Q1	$349K	Sell	3,210 -4,598	-59%	-$531K	0.04%	728
2019 Q4	$899K	Sell	7,808 -18,600	-70%	-$1.85M	0.07%	414
2019 Q3	$2.12M	Buy	+26,408	New	+$2.09M	0.13%	212

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaCrest Capital Management's ALNY Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 5,061 shares — an estimated $1.01M sold.

AlphaCrest Capital Management first reported a position in ALNY in Q3 2019 and held it in 12 quarters. The position peaked at $2.12M in Q3 2019. 488 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

AlphaCrest Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 5,061 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $1.01M.
AlphaCrest Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2019 and held it in 12 quarters.
AlphaCrest Capital Management's Alnylam Pharmaceuticals position peaked at $2.12M in Q3 2019.
488 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.